Ezharmia Tablet Post-marketing Surveillance

Ezharmia Tablet Post-marketing Surveillance (relapsed or refractory peripheral T-cell lymphoma)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031240338

Enrollment

150

Registered

2024-09-17

Start date

2024-06-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peripheral T-cell lymphoma: (PTCL)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who start receiving Ezharmia Tablet during the registration period.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Cumulative incidence of AEs (safety specifications : myelosuppression,infection and the secondary malignancy of the survey) and other AEs	—

Contacts

Public ContactGPSP Contact

Daiichi Sankyo Co.,Ltd.

contact_gpsp@daiichisankyo.co.jp+81-3-6225-1059

Outcome results